SCHEMBL25801943

SCHEMBL25801943

CCCCOc1ccc(-c2noc(CC(C(=O)OC(C)(C)C)P(C)(=O)OCC)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.45
ACACA Q13085 2/20 0.45
MITF O75030 1/20 0.44
TP53 P04637 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PSMB5 P28074 1/20 0.40
SMPD1 P17405 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
FFAR1 O14842 1/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 1/20 0.38
ADRB2 P07550 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23588079 0.92 ACACB (0.46) ACACBACACAMITFTP53NCOA3
SCHEMBL25801780 0.89 SPHK1 (0.43) MITFTP53NCOA3RAB9ANPC1
SCHEMBL25801802 0.89 SPHK1 (0.46) S1PR1S1PR3
SCHEMBL25802138 0.88 LMNA (0.48) LMNAPSMB5MAPTNPSR1TSHR
SCHEMBL25802128 0.87 LMNA (0.39) MITFTP53NCOA3RAB9ANPC1
SCHEMBL25802131 0.87 LMNA (0.39) MITFTP53NCOA3RAB9ANPC1
SCHEMBL25801755 0.87 HTT (0.48) TP53RAB9ANPC1LMNAMAPT
SCHEMBL25801993 0.86 RAB9A (0.37) TP53RAB9ANPC1LMNAMAPT
SCHEMBL25801911 0.86 MAPT (0.37) LMNAHSD17B10PSMB5SMPD1MAPT
SCHEMBL25802076 0.84 RAB9A (0.38) TP53RAB9ANPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 ACACB 358/4885ACACA 144/4885MITF 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.